Back to Newsroom

S1 Biopharma Prepares to Initiate Phase 2a Clinical Trial for Low Male Sexual Desire

Orexa will be the first drug ever to enter clinical trials for male HSDD

JERSEY CITY, N.J., March 3, 2014 — S1 Biopharma today announced its plan to initiate Phase 2a clinical trials in the third quarter of this year for Orexa (S1P-205), its first-in-class therapy to treat male Hypoactive Sexual Desire Disorder (HSDD). The double-blind placebo-controlled study will be the first to evaluate a drug for male HSDD.